secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2024-07-08T23:59:59+00:00
Accession:  0001867096-24-000124
Event type: leadership
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris CEO Paul Edick steps down; John Shannon named CEO; Q2 revenue >$47M (+23% YoY)
--------------------------------------------------------------------------------

- CEO Paul R. Edick transitions to Senior Advisor effective Aug 1, 2024; John Shannon (President & COO) appointed new CEO and Board member.
- Marla S. Persky appointed Chairperson of the Board effective Aug 1, 2024.
- Preliminary Q2 2024 total revenue exceeds $47.0M, representing >23% growth over prior year.
- Year-end 2024 cash guidance reaffirmed at $55M to $75M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/0001867096-24-000124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709624000124/xers-20240707.htm
  HTML page:      https://secwatch.observer/filing/0001867096-24-000124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer